AR045895A1 - Derivados de bencimidazol inhibidores de quinasas y metodos de preparacion - Google Patents

Derivados de bencimidazol inhibidores de quinasas y metodos de preparacion

Info

Publication number: AR045895A1
Authority: AR; Argentina
Prior art keywords: hal; group; independently selected; independently; conh2
Prior art date: 2003-07-11

Application number

ARP040102409A

Other languages

English (en)

Spanish (es)

Inventor

Amendt Christiane Dr

Buchstaller Hans-Peter Dr

Finsinger Dirk Dr

Wiesner Matthias Dr

Burgdorf Lars Dr

Grell Matthias Dr

Sirrenberg Christian Dr

Zenke Frank Dr

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2004-07-08

Publication date

2005-11-16

2004-07-08 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2005-11-16 Publication of AR045895A1 publication Critical patent/AR045895A1/es

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
229910052760 oxygen Inorganic materials 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 5
229910052717 sulfur Inorganic materials 0.000 abstract 5
229910052799 carbon Inorganic materials 0.000 abstract 3
125000001424 substituent group Chemical group 0.000 abstract 3
150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
101100509371 Arabidopsis thaliana CHR11 gene Proteins 0.000 abstract 1
101100495912 Arabidopsis thaliana CHR12 gene Proteins 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
-1 alkylenecycloalkyl Chemical group 0.000 abstract 1
229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 1
125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ARP040102409A 2003-07-11 2004-07-08 Derivados de bencimidazol inhibidores de quinasas y metodos de preparacion AR045895A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03015582		2003-07-11

Publications (1)

Publication Number	Publication Date
AR045895A1 true AR045895A1 (es)	2005-11-16

Family

ID=34042825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP040102409A AR045895A1 (es)	2003-07-11	2004-07-08	Derivados de bencimidazol inhibidores de quinasas y metodos de preparacion

Country Status (8)

Country	Link
US (1)	US7691886B2 (de)
EP (1)	EP1653951B1 (de)
JP (1)	JP4823903B2 (de)
AR (1)	AR045895A1 (de)
AT (1)	ATE538787T1 (de)
CA (1)	CA2531859C (de)
ES (1)	ES2380201T3 (de)
WO (1)	WO2005004864A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME00275B (me)	1999-01-13	2011-02-10	Bayer Corp	ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1158985B1 (de)	1999-01-13	2011-12-28	Bayer HealthCare LLC	GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7557129B2 (en)	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (de)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-harnstoffe mit kinasehemmender wirkung
JP5001650B2 (ja) *	2003-07-11	2012-08-15	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	ベンズイミダゾールカルボキサミド
EP1663978B1 (de)	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
CA2716947A1 (en) *	2008-02-29	2009-09-11	Array Biopharma Inc.	Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
JP2011513332A (ja) *	2008-02-29	2011-04-28	アレイバイオファーマ、インコーポレイテッド	癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
KR20100122505A (ko) *	2008-02-29	2010-11-22	어레이 바이오파마 인크.	Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
JP2011513331A (ja) *	2008-02-29	2011-04-28	アレイバイオファーマ、インコーポレイテッド	ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US8604217B2 (en)	2009-11-12	2013-12-10	Selvita S.A.	Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
CN102712601A (zh) *	2009-11-12	2012-10-03	赛尔维他股份公司	化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
US9629851B2 (en)	2013-09-20	2017-04-25	Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis	ROCK in combination with MAPK pathway
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
WO2016035897A1 (ja) *	2014-09-05	2016-03-10	日産化学工業株式会社	感光性無電解めっき下地剤
US20240116897A1 (en) *	2021-01-29	2024-04-11	Korea Research Institute Of Chemical Technology	Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4011236A (en) *	1968-09-09	1977-03-08	Merck & Co., Inc.	N-(benzimidazol-2-yl)arylcarboxamides as ultraviolet (uv) light absorbers
US4002623A (en)	1974-08-07	1977-01-11	Pfizer Inc.	Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines
UA71587C2 (uk) *	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2001021160A2 (en) *	1999-09-23	2001-03-29	Axxima Pharmaceuticals Aktiengesellschaft	Carboxymide and aniline derivatives as selective inhibitors of pathogens
JP2004517080A (ja) *	2000-11-29	2004-06-10	グラクソグループリミテッド	Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
US7122544B2 (en) *	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7132438B2 (en) *	2001-10-09	2006-11-07	Amgen Inc.	Benzimidazole derivatives
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
EP1388341A1 (de) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
US7338956B2 (en) *	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JP5001650B2 (ja)	2003-07-11	2012-08-15	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	ベンズイミダゾールカルボキサミド

2004
- 2004-06-15 EP EP04739891A patent/EP1653951B1/de not_active Expired - Lifetime
- 2004-06-15 AT AT04739891T patent/ATE538787T1/de active
- 2004-06-15 US US10/564,185 patent/US7691886B2/en not_active Expired - Fee Related
- 2004-06-15 JP JP2006519783A patent/JP4823903B2/ja not_active Expired - Fee Related
- 2004-06-15 WO PCT/EP2004/006419 patent/WO2005004864A1/en not_active Ceased
- 2004-06-15 CA CA2531859A patent/CA2531859C/en not_active Expired - Fee Related
- 2004-06-15 ES ES04739891T patent/ES2380201T3/es not_active Expired - Lifetime
- 2004-07-08 AR ARP040102409A patent/AR045895A1/es unknown

Also Published As

Publication number	Publication date
US20070010560A1 (en)	2007-01-11
US7691886B2 (en)	2010-04-06
EP1653951A1 (de)	2006-05-10
EP1653951B1 (de)	2011-12-28
JP2007513054A (ja)	2007-05-24
CA2531859A1 (en)	2005-01-20
ATE538787T1 (de)	2012-01-15
JP4823903B2 (ja)	2011-11-24
ES2380201T3 (es)	2012-05-09
AU2004255403A1 (en)	2005-01-20
CA2531859C (en)	2013-08-06
WO2005004864A1 (en)	2005-01-20

Legal Events

Date	Code	Title	Description
2007-08-14	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR045896A1 (es)	2005-11-16	Bencimidazolcarboxamidas
AR045895A1 (es)	2005-11-16	Derivados de bencimidazol inhibidores de quinasas y metodos de preparacion
AR047585A1 (es)	2006-01-25	Derivados de bisarilurea
AR054212A1 (es)	2007-06-13	Derivados de bisarilurea sustituidos con heterociclos, composicion farmaceutica y un metodo para prepararla y compuestos intermediarios de sintesis
AR042691A1 (es)	2005-06-29	Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
PE20091673A1 (es)	2009-11-14	Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
AR046244A1 (es)	2005-11-30	Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
PE20090816A1 (es)	2009-07-25	Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
RU2009117701A (ru)	2010-11-20	Производные пирролидина в качестве ингибиторов iap
AR036115A1 (es)	2004-08-11	Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
AR074002A1 (es)	2010-12-15	Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
AR060237A1 (es)	2008-06-04	Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
AR088304A1 (es)	2014-05-21	5,7-imidazo[1,2-c]pirimidinas sustituidas
AR041251A1 (es)	2005-05-11	Compuestos de fenilindol para modular la ige e inhibir la proliferacion celular
AR045761A1 (es)	2005-11-09	Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR073687A1 (es)	2010-11-24	Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
AR048642A1 (es)	2006-05-10	Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
BR9307595A (pt)	1999-09-08	Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis
DE60320012D1 (de)	2008-05-08	Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
RU2012116877A (ru)	2013-11-10	Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
AR071208A1 (es)	2010-06-02	Derivados de piridazinona
AR099498A1 (es)	2016-07-27	Compuestos de triazina y su uso farmacéutico
PE20120356A1 (es)	2012-04-16	Compuestos para el tratamiento de trastornos metabolicos
PE20110405A1 (es)	2011-07-04	Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
ECSP088829A (es)	2008-11-27	Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)